Innate Pharma

Quarterly Financials

Values in thousands 2025-03-31 2024-06-30 2024-03-31
Revenue
$276
$12,345
$21,443
Gross Profit
29,352
-16,731
-3,126
EBITDA
-21,348
-25,563
-10,396
EBIT
-22,592
-26,313
-12,270
Net Income
-24,707
-24,764
-9,288
Net Change In Cash
276
12,345
21,443
Free Cash Flow
-10,040
2,753
-21,135
Cash
66,396
69,990
70,605
Basic Shares
81,052
80,872
80,586

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$12,621
$51,901
$57,674
$12,112
Gross Profit
12,621
-4,121
-2,024
-34,892
EBITDA
-46,911
-1,839
-12,279
-43,229
EBIT
-48,905
-6,930
-57,684
-47,798
Net Income
-49,471
-7,570
-58,103
-59,136
Net Change In Cash
12,621
51,901
57,674
12,112
Free Cash Flow
-7,287
-34,909
-20,276
-59,787
Cash
66,396
70,605
84,225
103,756
Basic Shares
81,052
84,111
79,639
79,542

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
-$0.29
2025-03-31
-$0.30
2024-12-31
-$0.30